Myriad Genetics director Skovronsky resigns

Myriad Genetics, Inc. reported that Board member Daniel M. Skovronsky, M.D., Ph.D., resigned as a director effective June 17, 2026.

Accepted by SEC EDGAR 06/23/2026 - 08:32 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Myriad Genetics, Inc. reported that Board member Daniel M. Skovronsky, M.D., Ph.D., resigned as a director effective June 17, 2026. The company states his resignation was not due to any disagreement with Myriad Genetics or any matter related to its operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Director resignation effective date: June 17, 2026

1 metrics

Director resignation effective date June 17, 2026 Effective date of Daniel M. Skovronsky’s resignation

Key Terms

Board of Directors, Emerging growth company, Nasdaq Global Select Market

3 terms

Board of Directors financial

"a member of the Board of Directors of Myriad Genetics, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Global Select Market market

"MYGN | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Myriad Genetics (MYGN) announce in this 8-K filing?

Myriad Genetics announced that director Daniel M. Skovronsky, M.D., Ph.D., resigned from its Board effective June 17, 2026. The company noted the resignation was not related to disagreements over operations, policies, or practices.

When did Daniel M. Skovronsky resign from Myriad Genetics (MYGN)?

Daniel M. Skovronsky resigned as a director of Myriad Genetics effective June 17, 2026. The filing states he notified the company on that date and his resignation took effect immediately.

Did Daniel M. Skovronsky have any disagreements with Myriad Genetics (MYGN)?

The filing states that Daniel M. Skovronsky’s resignation was not the result of any disagreement with Myriad Genetics. It specifically notes no disputes regarding the company’s operations, policies, or practices.

What section of the 8-K filing covers the Myriad Genetics (MYGN) board change?

The board change is disclosed under Item 5.02, which covers departures of directors or certain officers and related appointments or compensatory arrangements. This item is used when reporting changes in key leadership positions.

Who signed the Myriad Genetics (MYGN) 8-K reporting the director resignation?

The 8-K was signed on behalf of Myriad Genetics by Benjamin R. Wheeler. He is identified in the filing as the company’s Chief Financial Officer and signed the report dated June 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-26642

87-0494517

(State or other jurisdiction of
incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

322 North 2200 West

Salt Lake City, Utah 84116

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

MYGN

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 17, 2026, Daniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”) notified the Company that he is resigning as a director, effective immediately. Dr. Skovronsky’s resignation was not a result of any disagreement with the Company or due to any matter relating to the Company’s operations, policies, or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	MYRIAD GENETICS, INC.

Date: June 23, 2026	By:	/s/ Benjamin R. Wheeler
		Benjamin R. Wheeler
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents